Simcha

Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors

Retrieved on: 
Wednesday, April 5, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Cancer, Coronavirus Scientific Advisory Board, Simcha, Patient, Merck & Co., Therapy, Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry, Merck, Pembrolizumab

Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced a clinical trial collaboration with Merck (known as MSD outside the US and Canada) to evaluate clinical safety and benefits of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors.

Key Points: 
  • Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced a clinical trial collaboration with Merck (known as MSD outside the US and Canada) to evaluate clinical safety and benefits of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors.
  • In conjunction with this collaboration, Dr. Emmett Schmidt, vice president of early oncology development for Merck, will join Simcha’s scientific advisory board.
  • “I’m excited to work with Dr. Schmidt, and we are eager to leverage Merck’s expertise to evaluate the clinical benefits of ST-067 in combination with Keytruda in hopes of bringing transformational medicines for cancer patients.”
    “I am delighted to join the Scientific Advisory Board at Simcha,” commented Dr. Schmidt.
  • “I look forward to directly contributing to the development of agents with the potential to benefit patients receiving Keytruda in combination with emerging combination agents.”
    KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Simcha Therapeutics Accelerates Growth with Key Leadership Appointments, Expanded Research and Option Agreement with Yale School of Medicine

Retrieved on: 
Tuesday, August 16, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Sequah Medicine Company, LIFE, Beatrice, Thomas Jefferson University, ATyr Pharma, CEO, Internal medicine, Wuxi, Cancer, SVKM's NMIMS, Thomas Jefferson University Hospital, Yale School of Medicine, Research, Kellogg School, Patient, Therapy, Company, Amgen, Skin, Bauer, PPD, Cytokine, Iron ring (laboratory), Radius Ventures, Organization, RNA transfection, Management, Pharmaceutical industry, Simcha, Medicine, Pfizer, Northwestern University

Simcha has also expanded its sponsored research agreement with Yale School of Medicine related to cytokine biology in the laboratory of Aaron Ring, Ph.D., M.D., associate professor of immunobiology and Simcha founder.

Key Points: 
  • Simcha has also expanded its sponsored research agreement with Yale School of Medicine related to cytokine biology in the laboratory of Aaron Ring, Ph.D., M.D., associate professor of immunobiology and Simcha founder.
  • Through this expanded agreement, the company will support research in the Ring Laboratory focused on overcoming biological limitations of native cytokines.
  • Simcha holds an exclusive option to license multiple therapeutic agents resulting from the expanded research agreement.
  • Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients.

Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1/2 Study to Evaluate Novel Interleukin-18 Variant in Cancer

Retrieved on: 
Thursday, January 27, 2022
Phase II, NEW, Cytokine, Leadership, Therapy, Doctor of Philosophy, Yale School of Medicine, Assistant, Biotechnology, Company, Series, Immune system, GLOBE, Yale school, Simcha Bunim of Peshischa, Safety, Pharmaceutical industry, Simcha, Nature, MD

NEW HAVEN, Conn., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, today announced the closing of a $40 million Series B financing. The round was led by SR One Capital Management and joined by other new investors including BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners, and Logos Capital. In conjunction with the financing, Simeon George, MD, Chief Executive Officer of SR One Capital Management, has joined the Simcha Therapeutics Board of Directors.

Key Points: 
  • In conjunction with the financing, Simeon George, MD, Chief Executive Officer of SR One Capital Management, has joined the Simcha Therapeutics Board of Directors.
  • The study is designed to evaluate the safety and bioactivity of ST-067 in a broad set of solid tumor types.
  • Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.
  • Simcha was founded in 2018 by Aaron Ring, MD, PhD, Assistant Professor of Immunobiology at the Yale School of Medicine.